Navigation Links
First human gets new antibody aimed at hepatitis C virus
Date:8/14/2009

Boston, Mass. Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

The first volunteer received the antibody known as MBL-HCV1 on July 28, 2009, and the study is now proceeding and will eventually involve 30 healthy subjects in a dose-escalation trial expected to conclude later this year. "We are pleased that this program has now entered the clinical trial phase," said Donna Ambrosino, MD, executive director of MassBiologics and a professor of pediatrics at the Medical School. "This trial will test the safety of the antibody and measure its activity in the subjects. This will help us determine the useful dose and other parameters as we plan for the next step in this program, which will be a Phase 2 study in liver transplant patients."

HCV attacks the liver and can eventually lead to liver failure. According to the U.S. Centers for Disease Control and Prevention, 3.2 million Americans are chronically infected with HCV and some 10,000 die annually of the disease. Globally, as many as 170 million people are estimated to suffer from HCV infection. For the most serious cases of HCV that do not respond to antiviral drugs, liver transplantation is the only option.

HCV is the leading indication for liver transplantation, diagnosed in about half of the 6,000 liver transplants done each year in the United States. Transplantation can be a life-saving treatment; however, in nearly all cases the patient's new liver is eventually infected by HCV because the virus remains in the patient's bloodstream during surgery. The powerful antiviral drugs now used to attack HCV prior to end-stage liver failure are not routinely used during surgery due to the patients' weakened condit
'/>"/>

Contact: Michael Cohen
Michael.Cohen@umassmed.edu
508-868-4778
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Vycom announced ... CA, which specializes in chemical process equipment, has selected ... State University’s Facility for Rare Isotope Beams (FRIB). ... precision cleaning line made with Vycom’s Flametec PVC-C and ... are the essential parts of FRIB’s linear accelerator (known ...
(Date:8/26/2014)... 2014  Guardant Health, a healthcare company focused ... products, has been recognized today by the World ... . As an innovator in non-invasive, tumor profiling, ... a wide variety of industries and regions to ... ® , Guardant Health,s first commercially available product, ...
(Date:8/26/2014)... 26, 2014 After searching for ... research facilities , the University of Kansas Medical ... have chosen iLab Solutions' web-based core facility management ... , "We are very pleased that the ... Center signed on with us,” stated Heather Lorenz, ...
Breaking Biology Technology:ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 3
... Company also Initiates the Phase 2b ASTUTE Clinical Trial ... Therapeutics, Inc., a privately held biopharmaceutical company, announced that ... the treatment of patients with low-grade hepatic encephalopathy was ... the European Association for the Study of Liver Disease ...
... palliation as an acceptable primary endpoint, ... WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... has reached an agreement with the U.S. Food and ... Phase 3 registration trial of OGX-011, its lead product ...
... compliance and persistence with chronic medications. Prescription refills increase up ... free service offers coaching, reminders and pharmacist support to alleviate ... - prescribed medication. , ... ...
Cached Biology Technology:Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6New Pleio Medication Adherence Service Increases Prescription Refills Up To 53% 2
(Date:8/26/2014)... in St. Louis have developed algorithms to identify weak ... or breaking. The technology, which needs to be refined ... help pinpoint minor strains and tiny injuries in the ... research is available online Aug. 27 in the ... research at the nexus of the physical and life ...
(Date:8/26/2014)... a pen a New Zealand endemic tree has for the ... group of ,weedy, Australian shrubs and small trees. A New ... surprises and discover astonishing cryptic diversity behind what was long ... the open access journal PhytoKeys . , ... was one of the many discoveries made in the north-western ...
(Date:8/26/2014)... -- Unregulated trash burning around the globe is pumping ... official records. A new study led by the National ... percent of the world,s garbage is burned in such ... human health and climate change. , The new study ... of pollutants such as particulates, carbon monoxide, and mercury ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3
... Fifty-nine leading life scientists from Europe and around the ... Organization (EMBO) for their proven excellence in research. Fifty-one ... Europe and neighbouring countries, while eight equally respected scientists ... as Associate Members, bringing the current membership total to ...
... herbicide that is effective at killing broadleaf weeds in ... Illinois and other Midwestern states, may finally have a ... developed a new grape called Improved Chancellor which is ... 1946, 2,4-Dichlorophenoxyacetic or 2, 4-D was introduced. It was ...
... is available in Spanish . An ... the Institute for Research in Biomedicine (IRB Barcelona) and ... (ICIQ, Tarragona), have discovered a substance with the capacity ... certain mutations that promote the appearance of cancer. Giralt, ...
Cached Biology News:EMBO honors 59 leading life scientists 2Herbicide-resistant grape could revitalize Midwest wine industry 2Herbicide-resistant grape could revitalize Midwest wine industry 3Design of a compound that stabilizes the main natural suppressor of tumors 2
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Test Plate consists of an anodized aluminum ... Organic Fluorescent Compounds embedded in polymerized matrix. ... BioTeks FLx800 and Synergy Multi-Detection Readers. This ... compliance while reducing the need for tedious ...
Biology Products: